Sanofi, Regeneron cut Praluent list price by 60%

Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are dropping the list price of PCSK9 inhibitor Praluent alirocumab by 60% to match the

Read the full 235 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE